Literature DB >> 32447376

Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study.

Guillaume Gauchotte1,2,3, Matthieu Peyre4,5, Celso Pouget1,2, Dominique Cazals-Hatem6, Marc Polivka7, Fabien Rech8,9, Pascale Varlet10, Hugues Loiseau11,12, Stéphanie Lacomme3, Karima Mokhtari4,13, Michel Kalamarides4,5, Franck Bielle4,13,14.   

Abstract

The diagnosis of anaplastic meningioma (AM) (WHO grade III) is based on the presence of a high mitotic index (MI) and/or overt anaplasia. Only few data exist about the reproducibility and prognostic value of overt anaplasia. Additionally, the prognostic value of H3K27me3 loss in AM has not yet been demonstrated. Our objectives were to evaluate the reproducibility and prognostic value of WHO criteria and H3K27me3 loss in a multicenter series of 66 AM. Interobserver reproducibility was good for the determination of WHO grade (Kappa = 0.671) and MI (intraclass correlation coefficient [ICC] = 0.649), and fair for assessment of overt anaplasia (Kappa = 0.366). Patients with meningiomas showing high MI had significantly shorter overall survival (OS) than patients with meningiomas showing overt anaplasia without high MI (p = 0.009). OS was significantly lower in case of overt anaplasia with low MI (<20/1.6 mm2) than in atypical meningiomas (p = 0.008). H3K27me3 loss was present in 10/47 (21%) of AM and independently associated with shorter OS (p = 0.036; Cox multivariate analysis), with a good reproducibility (Kappa = 0.643). In conclusion, the presence of overt anaplasia could give additional prognostic information in tumors lacking high MI. Finally, loss of H3K27me3 is an easy-to-use and reproducible marker of poorer prognosis.
© 2020 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Anaplasia; Anaplastic meningioma; H3K27me3; Mitotic index; Prognosis

Year:  2020        PMID: 32447376     DOI: 10.1093/jnen/nlaa038

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  12 in total

1.  Loss of H3K27me3 in WHO grade 3 meningioma.

Authors:  Andrea Daniela Maier; Christian Beltoft Brøchner; Christian Mirian; Jeppe Haslund-Vinding; Jiri Bartek; Tomas J Ekström; Frantz Rom Poulsen; David Scheie; Tiit Mathiesen
Journal:  Brain Tumor Pathol       Date:  2022-06-09       Impact factor: 3.154

2.  A molecularly integrated grade for meningioma.

Authors:  Joseph Driver; Samantha E Hoffman; Sherwin Tavakol; Eleanor Woodward; Eduardo A Maury; Varun Bhave; Noah F Greenwald; Farshad Nassiri; Kenneth Aldape; Gelareh Zadeh; Abrar Choudhury; Harish N Vasudevan; Stephen T Magill; David R Raleigh; Malak Abedalthagafi; Ayal A Aizer; Brian M Alexander; Keith L Ligon; David A Reardon; Patrick Y Wen; Ossama Al-Mefty; Azra H Ligon; Adrian M Dubuc; Rameen Beroukhim; Elizabeth B Claus; Ian F Dunn; Sandro Santagata; Wenya Linda Bi
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

3.  Prognostication for meningiomas: H3K27me3 to the rescue?

Authors:  Sandro Santagata; Keith L Ligon
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

4.  Loss of H3K27me3 in meningiomas.

Authors:  Farshad Nassiri; Justin Z Wang; Olivia Singh; Shirin Karimi; Tatyana Dalcourt; Nazanin Ijad; Neda Pirouzmand; Ho-Keung Ng; Andrea Saladino; Bianca Pollo; Francesco Dimeco; Stephen Yip; Andrew Gao; Kenneth D Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

5.  Why we need new classification models in meningioma management.

Authors:  Marco V Corniola
Journal:  Acta Neurochir (Wien)       Date:  2022-01-24       Impact factor: 2.216

6.  H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.

Authors:  Felix Behling; Christina Fodi; Irina Gepfner-Tuma; Kristina Kaltenbach; Mirjam Renovanz; Frank Paulsen; Marco Skardelly; Jürgen Honegger; Marcos Tatagiba; Jens Schittenhelm; Ghazaleh Tabatabai
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

7.  The Immunohistochemical Loss of H3K27me3 in Intracranial Meningiomas Predicts Shorter Progression-Free Survival after Stereotactic Radiosurgery.

Authors:  Serena Ammendola; Paola Chiara Rizzo; Michele Longhi; Emanuele Zivelonghi; Serena Pedron; Giampietro Pinna; Francesco Sala; Antonio Nicolato; Aldo Scarpa; Valeria Barresi
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

Review 8.  Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review.

Authors:  Atsushi Okano; Satoru Miyawaki; Yu Teranishi; Kenta Ohara; Hiroki Hongo; Yu Sakai; Daiichiro Ishigami; Hirofumi Nakatomi; Nobuhito Saito
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-07-22       Impact factor: 2.036

Review 9.  A simplified overview of the World Health Organization classification of central nervous system tumors 2021.

Authors:  Hanuman Prasad Prajapati; Sanjay Kumar Kannaujia
Journal:  Surg Neurol Int       Date:  2022-06-17

Review 10.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.